Gavin MacBeath (TCRX) receives 1,165,000 TScan stock options

Rhea-AI Filing Summary

TScan Therapeutics, Inc. granted stock options to its Chief Executive Officer and director, Gavin MacBeath. On January 20, 2026, he received a stock option to purchase 1,165,000 shares of voting common stock at an exercise price of $1.12 per share. The option was granted at no cost for the derivative itself.

According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on the one-year anniversary of January 20, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting is conditioned on his continued service to the company on each vesting date. Following this grant, MacBeath beneficially owned 1,165,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MacBeath Gavin

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	01/20/2026		A		1,165,000		(1)	01/20/2036	Voting Common Stock	1,165,000	$0.00	1,165,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Zoran Zdraveski, Attorney-in-Fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TScan Therapeutics (TCRX) disclose in this Form 4 filing?

TScan Therapeutics disclosed that its Chief Executive Officer and director, Gavin MacBeath, was granted a stock option on January 20, 2026 covering 1,165,000 shares of voting common stock at an exercise price of $1.12 per share.

How many stock options did TScan CEO Gavin MacBeath receive?

Gavin MacBeath received a stock option to purchase 1,165,000 shares of TScan Therapeutics voting common stock. After this grant, he beneficially owned 1,165,000 derivative securities directly.

What is the exercise price and term of the TScan CEO’s stock option grant?

The stock option granted to Gavin MacBeath has an exercise price of $1.12 per share and an expiration date of January 20, 2036, giving him the right to buy up to 1,165,000 shares at that price before it expires.

How do the TScan CEO’s stock options vest over time?

The option vests with respect to 25% of the shares on the one-year anniversary of January 20, 2026. The remaining 75% vests in equal monthly installments over the next 36 months, subject to his continued service to the company on each vesting date.

Is Gavin MacBeath’s ownership in TScan reported as direct or indirect?

The Form 4 indicates that the 1,165,000 derivative securities (stock options) are held with direct (D) ownership by Gavin MacBeath, with no separate indirect ownership entity noted.

What roles does Gavin MacBeath hold at TScan Therapeutics (TCRX)?

According to the filing, Gavin MacBeath is both a director and an officer of TScan Therapeutics, serving as the company’s Chief Executive Officer.